🚀 This method enhances recombinant protein production speed and quality.
🔬 It ensures glycosylation consistency, crucial for therapeutic proteins.
👩🔬 The system achieved impressive protein yields, maintaining quality from transient to stable stages.
✨ QLNS-CHO sets a new standard for transient expression platforms in biopharmaceuticals.
Introduction:
This article discusses the development of a novel transient transfection system based on CHO-K1 cells, referred to as QLNS-CHO, which aims to provide consistent quality in recombinant protein production in biopharmaceutical development, bridging the gap between transient and stable expression methods.
- The transient transfection method has become vital for faster recombinant protein production compared to stable transfection, which is more time-intensive.
- Existing transient expression platforms predominantly use CHO-S cells, leading to concerns about glycosylation variability in therapeutic proteins.
- The QLNS-CHO system incorporates a transposon-containing plasmid that enhances gene expression and cell viability.
- Polyethyleneimine is used as a transfection reagent, which, along with optimized cultivation parameters, allows for high protein titers, reaching 1.5 g/L for certain bispecific antibodies.
- The QLNS-CHO system demonstrated consistency in cellular quality between transient and stable production stages, crucial for developing high-quality therapeutic antibodies.
Conclusion:
The QLNS-CHO transient expression system not only increases the efficiency of protein production but also ensures quality consistency that is paramount in the biopharmaceutical sector. This innovative approach offers a promising pathway for drug developers to enhance the speed and reliability of bringing biopharmaceuticals to clinical trials, thereby reducing overall development risks and resource expenditure.
